Bacillus Calmette-Guerin lymphadenitis: A 6-year experience in two Saudi hospitals.

Simple item page
dc.contributor.authorBukhari, E
dc.contributor.authorAlzahrani, M
dc.contributor.authorAlsubaie, S
dc.contributor.authorAlrabiaah, A
dc.contributor.authorAlzamil, F
dc.date.accessioned2012-10-17T05:28:50Z
dc.date.available2012-10-17T05:28:50Z
dc.date.issued2012-04
dc.description.abstractBackground : The World Health Organization (WHO) has recommended Bacillus Calmette-Guerin (BCG) vaccination as a part of the global expanded program for immunization. Although the BCG vaccine is usually a safe vaccine, a number of complications with lymphadenitis being the most common complication, can occur. Aim : We evaluated the frequency, the clinical presentation and treatment modalities of lymphadenitis after BCG vaccine in Saudi children. Results : A total of 145 patients with BCG lymphadenitis presented between January 2005 and December 2010. In the majority (103) of the cases, the lymphadenitis involved ipsilateral left axillary nodes. Other sites of involvement included the left supraclavicular lymph nodes in 26 (18%) patients, and both the left axillary and supraclavicular lymph nodes were involved in 7 cases (4.8%). A total of 75 patients (65%) were given antituberculous medication. Eight (27%) patients had positive acid-fast bacilli and positive cultures for Mycobacterium bovis. Conclusion : In light of the findings of this study, it would be advisable to administer the BCG vaccine in Saudi Arabia at a time later than at birth, as the younger children are commonly affected.en_US
dc.identifier.citationBukhari E, Alzahrani M, Alsubaie S, Alrabiaah A, Alzamil F. Bacillus Calmette-Guerin lymphadenitis: A 6-year experience in two Saudi hospitals. Indian Journal of Pathology & Microbiology. 2012 Apr-Jun 55(2): 202-205.en_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/142222
dc.language.isoenen_US
dc.source.urihttps://www.ijpmonline.org/article.asp?issn=0377-4929;year=2012;volume=55;issue=2;spage=202;epage=205;aulast=Bukharien_US
dc.subjectBacillus Calmette-Guerinen_US
dc.subjectlymphadenitisen_US
dc.subjecttuberculosisen_US
dc.subject.meshAge Factors
dc.subject.meshAntitubercular Agents --therapeutic use
dc.subject.meshBCG Vaccine --adverse effects
dc.subject.meshDrug Toxicity --drug therapy
dc.subject.meshDrug Toxicity --epidemiology
dc.subject.meshDrug Toxicity --pathology
dc.subject.meshHospitals
dc.subject.meshHumans
dc.subject.meshInfant
dc.subject.meshLymphadenitis --drug therapy
dc.subject.meshLymphadenitis --epidemiology
dc.subject.meshLymphadenitis --microbiology
dc.subject.meshLymphadenitis --pathology
dc.subject.meshMale
dc.subject.meshMycobacterium bovis --isolation & purification
dc.subject.meshPrevalence
dc.subject.meshSaudi Arabia --epidemiology
dc.titleBacillus Calmette-Guerin lymphadenitis: A 6-year experience in two Saudi hospitals.en_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
ijpm2012v55n2p202.pdf
Size:
567.52 KB
Format:
Adobe Portable Document Format
Description:
Journal article
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Indian Journal of Pathology & Microbiology